EcoDrugPlus

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSEEEG00000001707
Gene Symbol: GUCY1A2
2 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSEEEG00000004720
Gene Symbol: GUCY1B1
4 Cross references
211 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSEEEG00000009747
Gene Symbol: HSP90AA1.2
4 Cross references
317 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSEEEG00000012819
Gene Symbol: HSP90AB1
4 Cross references
357 Possible Orthologues:

Heat Shock Protein Hsp 90-Alpha 1

Ensembl ID : ENSEEEG00000011928
Gene Symbol: LOC113569657
4 Cross references
305 Possible Orthologues:

High Mobility Group Box 1a

Ensembl ID : ENSEEEG00000002498
Gene Symbol: HMGB1A
4 Cross references
454 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSEEEG00000021224
Gene Symbol: HMGB1B
4 Cross references
510 Possible Orthologues:

Histamine Receptor H1

Ensembl ID : ENSEEEG00000002046
Gene Symbol: HRH1
4 Cross references
186 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSEEEG00000009359
Gene Symbol: HRH2A
1 Cross references
192 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSEEEG00000008709
Gene Symbol: HDAC1
4 Cross references
307 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSEEEG00000003633
Gene Symbol: HDAC10
4 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSEEEG00000006040
Gene Symbol: HDAC11
4 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).